Insider Buying: Retension Pharmaceuticals (NASDAQ:RTSN) CEO Purchases $249,600.00 in Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) CEO Eric Keller purchased 20,800 shares of Retension Pharmaceuticals stock in a transaction that occurred on Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the transaction, the chief executive officer directly owned 423,377 shares of the company’s stock, valued at $5,080,524. This represents a 5.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Retension Pharmaceuticals Price Performance

Shares of NASDAQ RTSN opened at $12.21 on Friday. Retension Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $12.86.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.